cbdMD, Inc.

NYSEAM:YCBD.PRA Stock Report

Market Cap: US$2.2m

cbdMD Future Growth

Future criteria checks 0/6

cbdMD is forecast to grow earnings and revenue by 107.9% and 5.2% per annum respectively while EPS is expected to grow by 118.9% per annum.

Key information

107.9%

Earnings growth rate

118.9%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate5.2%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:YCBD.PRA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202522-4N/AN/A1
9/30/202420-8N/AN/A1
6/30/202421-23-1-1N/A
3/31/202422-26-2-1N/A
12/31/202323-24-3-2N/A
9/30/202324-27-5-4N/A
6/30/202326-26-6-6N/A
3/31/202329-56-8-8N/A
12/31/202232-59-12-12N/A
9/30/202235-74-16-15N/A
6/30/202237-63-18-17N/A
3/31/202239-29-20-20N/A
12/31/202141-37-18-17N/A
9/30/202144-26-14-14N/A
6/30/202146-28-10-10N/A
3/31/202146-38-6-7N/A
12/31/202044-10-9-8N/A
9/30/20204212-12-11N/A
6/30/20204031-19-17N/A
3/31/20203715-23-20N/A
12/31/201933-32-21-19N/A
9/30/201924-45-17-15N/A
6/30/20198-60-10-10N/A
3/31/20193-35-7-6N/A
12/31/20180-2-5-5N/A
9/30/20180-2-6-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: YCBD.PRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: YCBD.PRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: YCBD.PRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: YCBD.PRA's revenue (5.2% per year) is forecast to grow slower than the US market (8.9% per year).

High Growth Revenue: YCBD.PRA's revenue (5.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if YCBD.PRA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y